Associations between vitamin D levels and polycystic ovary syndrome phenotypes.


Journal

Minerva endocrinologica
ISSN: 1827-1634
Titre abrégé: Minerva Endocrinol
Pays: Italy
ID NLM: 8406505

Informations de publication

Date de publication:
Jun 2019
Historique:
pubmed: 14 4 2018
medline: 18 12 2019
entrez: 14 4 2018
Statut: ppublish

Résumé

Studies comparing serum 25-hydroxyvitamin D concentrations in women with and without polycystic ovary syndrome (PCOS) have produced inconsistent results. Additionally, no previous studies have evaluated associations between vitamin D and specific PCOS phenotypes. This case-control study was conducted among women undergoing intrauterine insemination. Cases (N.=137) were diagnosed with PCOS and then further classified into 3 diagnostic phenotypes based on combinations of the Rotterdam criteria (ovulatory dysfunction+polycystic ovaries [N.=55]; ovulatory dysfunction +androgen excess [N.=15]; and ovulatory dysfunction, +polycystic ovaries, +androgen excess [N.=67]). Controls (N.=103) were ovulatory women without PCOS who were undergoing IUI. Serum total 25-hydroxyvitamin D concentrations were categorized as deficient (≤20 ng/mL), insufficient (21-29 ng/mL), and sufficient (≥30 ng/mL). Prevalence odds ratios (PORs) were calculated using logistic regression. A higher proportion (59.9%) of PCOS cases lacked sufficient vitamin D levels compared to controls (47.6%; P value=0.06). The odds of vitamin D deficiency in all PCOS cases were twice that of controls (POR=2.03, 95% CI 0.97-4.26); however, the association was attenuated after adjusting for Body Mass Index (BMI) and race/ethnicity (adjPOR=1.43, 95% CI 0.62, 3.26). When examining PCOS phenotypes exhibiting androgen excess, crude associations were observed for deficient vitamin D levels (unadjPOR=2.93, 95% CI: 1.27, 6.77); however, the association decreased after adjustment for BMI and race/ethnicity (adjPOR=2.03, 95% CI: 0.79, 5.19). Vitamin D deficiency occurred more frequently in PCOS cases with androgen excess, but associations were attenuated after adjusting for BMI and race/ethnicity. Combining etiologically distinct PCOS subgroups may obscure associations with lower vitamin D levels and other potential risk factors.

Sections du résumé

BACKGROUND BACKGROUND
Studies comparing serum 25-hydroxyvitamin D concentrations in women with and without polycystic ovary syndrome (PCOS) have produced inconsistent results. Additionally, no previous studies have evaluated associations between vitamin D and specific PCOS phenotypes.
METHODS METHODS
This case-control study was conducted among women undergoing intrauterine insemination. Cases (N.=137) were diagnosed with PCOS and then further classified into 3 diagnostic phenotypes based on combinations of the Rotterdam criteria (ovulatory dysfunction+polycystic ovaries [N.=55]; ovulatory dysfunction +androgen excess [N.=15]; and ovulatory dysfunction, +polycystic ovaries, +androgen excess [N.=67]). Controls (N.=103) were ovulatory women without PCOS who were undergoing IUI. Serum total 25-hydroxyvitamin D concentrations were categorized as deficient (≤20 ng/mL), insufficient (21-29 ng/mL), and sufficient (≥30 ng/mL). Prevalence odds ratios (PORs) were calculated using logistic regression.
RESULTS RESULTS
A higher proportion (59.9%) of PCOS cases lacked sufficient vitamin D levels compared to controls (47.6%; P value=0.06). The odds of vitamin D deficiency in all PCOS cases were twice that of controls (POR=2.03, 95% CI 0.97-4.26); however, the association was attenuated after adjusting for Body Mass Index (BMI) and race/ethnicity (adjPOR=1.43, 95% CI 0.62, 3.26). When examining PCOS phenotypes exhibiting androgen excess, crude associations were observed for deficient vitamin D levels (unadjPOR=2.93, 95% CI: 1.27, 6.77); however, the association decreased after adjustment for BMI and race/ethnicity (adjPOR=2.03, 95% CI: 0.79, 5.19).
CONCLUSIONS CONCLUSIONS
Vitamin D deficiency occurred more frequently in PCOS cases with androgen excess, but associations were attenuated after adjusting for BMI and race/ethnicity. Combining etiologically distinct PCOS subgroups may obscure associations with lower vitamin D levels and other potential risk factors.

Identifiants

pubmed: 29652114
pii: S0391-1977.18.02824-9
doi: 10.23736/S0391-1977.18.02824-9
pmc: PMC6467740
mid: NIHMS1021092
doi:

Substances chimiques

Vitamin D 1406-16-2
25-hydroxyvitamin D A288AR3C9H

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

176-184

Subventions

Organisme : NIGMS NIH HHS
ID : U54 GM104938
Pays : United States

Références

Diabetes Care. 1999 Jan;22(1):141-6
pubmed: 10333916
Am J Clin Nutr. 2000 Sep;72(3):690-3
pubmed: 10966885
J Clin Endocrinol Metab. 2001 Apr;86(4):1626-32
pubmed: 11297595
Hum Reprod Update. 2001 Nov-Dec;7(6):522-5
pubmed: 11727859
Best Pract Res Clin Endocrinol Metab. 2002 Jun;16(2):263-72
pubmed: 12064892
J Clin Endocrinol Metab. 2003 Jan;88(1):157-61
pubmed: 12519845
Metabolism. 2003 Jul;52(7):908-15
pubmed: 12870169
Hum Reprod. 1992 Jul;7(6):735-45
pubmed: 1323571
J Clin Endocrinol Metab. 2004 Jun;89(6):2745-9
pubmed: 15181052
Clin Biochem. 2004 Oct;37(10):867-74
pubmed: 15369717
Clin Chem. 2005 Jan;51(1):258-61
pubmed: 15613728
N Engl J Med. 2005 Mar 24;352(12):1223-36
pubmed: 15788499
Clin Chem. 2005 Sep;51(9):1691-7
pubmed: 16037412
J Clin Endocrinol Metab. 2006 Mar;91(3):786-9
pubmed: 16418209
Fertil Steril. 2006 Jul;86(1):1-12
pubmed: 16750830
Pediatrics. 2006 Nov;118(5):e1390-8
pubmed: 17079540
Exp Clin Endocrinol Diabetes. 2006 Nov;114(10):577-83
pubmed: 17177140
Br J Nutr. 2009 Jan;101(2):278-84
pubmed: 18430263
Am J Clin Nutr. 2008 Aug;88(2):507S-510S
pubmed: 18689391
Arch Gynecol Obstet. 2009 Oct;280(4):559-63
pubmed: 19214546
Fertil Steril. 2010 Mar 1;93(4):1208-14
pubmed: 19230880
Arch Intern Med. 2009 Mar 23;169(6):626-32
pubmed: 19307527
Fertil Steril. 2010 Sep;94(4):1314-9
pubmed: 19589516
Eur J Endocrinol. 2009 Oct;161(4):575-82
pubmed: 19628650
Hum Reprod. 2010 Feb;25(2):544-51
pubmed: 19910321
Hum Reprod Update. 2010 May-Jun;16(3):231-45
pubmed: 19934213
Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):938-46
pubmed: 20332276
Best Pract Res Clin Endocrinol Metab. 2010 Aug;24(4):527-39
pubmed: 20832734
J Nutr. 2010 Nov;140(11):2030S-45S
pubmed: 20881084
Am J Clin Nutr. 2010 Dec;92(6):1446-51
pubmed: 20926524
Metabolism. 2011 Oct;60(10):1475-81
pubmed: 21550088
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30
pubmed: 21646368
Nitric Oxide. 2011 Oct 30;25(3):326-30
pubmed: 21741493
Clin Chim Acta. 2012 Jan 18;413(1-2):203-6
pubmed: 21983164
Am J Epidemiol. 2012 May 15;175(10):1029-36
pubmed: 22312120
ISRN Endocrinol. 2012;2012:949427
pubmed: 22363895
ISRN Obstet Gynecol. 2012;2012:691486
pubmed: 22523695
J Clin Endocrinol Metab. 2013 Jan;98(1):97-104
pubmed: 23144464
Trans Am Clin Climatol Assoc. 2012;123:209-19; discussion 219-20
pubmed: 23303986
Eur J Clin Nutr. 2013 Jun;67(6):680-2
pubmed: 23422920
J Clin Endocrinol Metab. 2013 Dec;98(12):4565-92
pubmed: 24151290
Eur Rev Med Pharmacol Sci. 2014 Oct;18(19):2851-6
pubmed: 25339479
Nutrients. 2015 Jun 08;7(6):4555-77
pubmed: 26061015
Am J Obstet Gynecol. 2016 Feb;214(2):247.e1-247.e11
pubmed: 26704896
J Clin Endocrinol Metab. 1999 Jan;84(1):165-9
pubmed: 9920077

Auteurs

Erin M Davis (EM)

Department of Anatomical Sciences and Neurobiology, University of Louisville, Louisville, KY, USA - erin.davis@louisville.edu.

Jennifer D Peck (JD)

Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Karl R Hansen (KR)

, Section of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Barbara R Neas (BR)

Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

LaTasha B Craig (LB)

, Section of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH